SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-102517"
 

Search: onr:"swepub:oai:DiVA.org:uu-102517" > Clinical benefit an...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone : a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001

Bernhard, Jürg (author)
Dietrich, Daniel (author)
Scheithauer, Werner (author)
show more...
Gerber, Daniela (author)
Bodoky, György (author)
Ruhstaller, Thomas (author)
Glimelius, Bengt (author)
Karolinska Institutet,Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi
Bajetta, Emilio (author)
Schüller, Johannes (author)
Saletti, Piercarlo (author)
Bauer, Jean (author)
Figer, Arie (author)
Pestalozzi, Bernhard C. (author)
Köhne, Claus-Henning (author)
Mingrone, Walter (author)
Stemmer, Salomon M. (author)
Tàmas, Karin (author)
Kornek, Gabriela V. (author)
Koeberle, Dieter (author)
Herrmann, Richard (author)
show less...
 (creator_code:org_t)
2008
2008
English.
In: Journal of Clinical Oncology. - 0732-183X .- 1527-7755. ; 26:22, s. 3695-3701
Related links:
https://urn.kb.se/re...
show more...
https://doi.org/10.1...
http://kipublication...
show less...
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • PURPOSE: To compare clinical benefit response (CBR) and quality of life (QOL) in patients receiving gemcitabine (Gem) plus capecitabine (Cap) versus single-agent Gem for advanced/metastatic pancreatic cancer. PATIENTS AND METHODS: Patients were randomly assigned to receive GemCap (oral Cap 650 mg/m(2) twice daily on days 1 through 14 plus Gem 1,000 mg/m(2) in a 30-minute infusion on days 1 and 8 every 3 weeks) or Gem (1,000 mg/m(2) in a 30-minute infusion weekly for 7 weeks, followed by a 1-week break, and then weekly for 3 weeks every 4 weeks) for 24 weeks or until progression. CBR criteria and QOL indicators were assessed over this period. CBR was defined as improvement from baseline for >or= 4 consecutive weeks in pain (pain intensity or analgesic consumption) and Karnofsky performance status, stability in one but improvement in the other, or stability in pain and performance status but improvement in weight. RESULTS: Of 319 patients, 19% treated with GemCap and 20% treated with Gem experienced a CBR, with a median duration of 9.5 and 6.5 weeks, respectively (P < .02); 54% of patients treated with GemCap and 60% treated with Gem had no CBR (remaining patients were not assessable). There was no treatment difference in QOL (n = 311). QOL indicators were improving under chemotherapy (P < .05). These changes differed by the time to failure, with a worsening 1 to 2 months before treatment failure (all P < .05). CONCLUSION: There is no indication of a difference in CBR or QOL between GemCap and Gem. Regardless of their initial condition, some patients experience an improvement in QOL on chemotherapy, followed by a worsening before treatment failure.

Keyword

MEDICINE
MEDICIN

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view